Bang et al. reported that the overall response rate of pembrolizumab (by central review) in advanced PD-L1-positive gastric cancer was 22.2 % [95 % confidence interval, 10.1–39.2] in a phase I study (KEYNOTE-012 study, gastric cancer cohort) [14]. This evidence concerns the gene CD274 and gastric cancer.